209 related articles for article (PubMed ID: 21673069)
1. EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients.
Hu-Lieskovan S; Vallbohmer D; Zhang W; Yang D; Pohl A; Labonte MJ; Grimminger PP; Hölscher AH; Semrau R; Arnold D; Dellas K; Debucquoy A; Haustermans K; Machiels JP; Sempoux C; Rödel C; Bracko M; Velenik V; Lenz HJ
Clin Cancer Res; 2011 Aug; 17(15):5161-9. PubMed ID: 21673069
[TBL] [Abstract][Full Text] [Related]
2. KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.
Kim SY; Shim EK; Yeo HY; Baek JY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Jung KH; Chang HJ
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):201-7. PubMed ID: 22672749
[TBL] [Abstract][Full Text] [Related]
3. Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study.
Kim SY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Lee KS; Yun T; Jeong SY; Choi HS; Lim SB; Chang HJ; Jung KH
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):677-83. PubMed ID: 20888703
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer.
Grimminger PP; Danenberg P; Dellas K; Arnold D; Rödel C; Machiels JP; Haustermans K; Debucquoy A; Velenik V; Sempoux C; Bracko M; Hölscher AH; Semrau R; Yang D; Danenberg K; Lenz HJ; Vallböhmer D
Clin Cancer Res; 2011 May; 17(10):3469-77. PubMed ID: 21558395
[TBL] [Abstract][Full Text] [Related]
5. Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase II study.
Sun PL; Li B; Ye QF
Int J Colorectal Dis; 2012 Oct; 27(10):1325-32. PubMed ID: 22430888
[TBL] [Abstract][Full Text] [Related]
6. Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.
Sclafani F; Chau I; Cunningham D; Peckitt C; Lampis A; Hahne JC; Braconi C; Tabernero J; Glimelius B; Cervantes A; Begum R; Gonzalez De Castro D; Hulkki Wilson S; Eltahir Z; Wotherspoon A; Tait D; Brown G; Oates J; Valeri N
Ann Oncol; 2015 Sep; 26(9):1936-1941. PubMed ID: 26162609
[TBL] [Abstract][Full Text] [Related]
7. Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer.
Garcia-Aguilar J; Chen Z; Smith DD; Li W; Madoff RD; Cataldo P; Marcet J; Pastor C
Ann Surg; 2011 Sep; 254(3):486-92; discussion 492-3. PubMed ID: 21865946
[TBL] [Abstract][Full Text] [Related]
8. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.
Pander J; Gelderblom H; Antonini NF; Tol J; van Krieken JH; van der Straaten T; Punt CJ; Guchelaar HJ
Eur J Cancer; 2010 Jul; 46(10):1829-34. PubMed ID: 20418097
[TBL] [Abstract][Full Text] [Related]
9. The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer.
Garm Spindler KL; Pallisgaard N; Rasmussen AA; Lindebjerg J; Andersen RF; Crüger D; Jakobsen A
Ann Oncol; 2009 May; 20(5):879-84. PubMed ID: 19179548
[TBL] [Abstract][Full Text] [Related]
10. Preoperative chemoradiation therapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: long-term results of a prospective phase 1/2 study.
Fokas E; Conradi L; Weiss C; Sprenger T; Middel P; Rau T; Dellas K; Kitz J; Rödel F; Sauer R; Rüschoff J; Beissbarth T; Arnold D; Ghadimi BM; Rödel C; Liersch T
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):992-9. PubMed ID: 24210078
[TBL] [Abstract][Full Text] [Related]
11. Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients.
Winder T; Zhang W; Yang D; Ning Y; Bohanes P; Gerger A; Wilson PM; Pohl A; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ
Clin Cancer Res; 2010 Nov; 16(22):5591-602. PubMed ID: 20935157
[TBL] [Abstract][Full Text] [Related]
12. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
13. A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer.
Cubillo A; Hernando-Requejo O; García-García E; Rodriguez-Pascual J; De Vicente E; Morelli P; Rubio C; López-Ríos F; Muro A; López U; Prados S; Quijano Y; Hidalgo M
Am J Clin Oncol; 2014 Apr; 37(2):117-21. PubMed ID: 23211222
[TBL] [Abstract][Full Text] [Related]
14. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
Bibeau F; Lopez-Crapez E; Di Fiore F; Thezenas S; Ychou M; Blanchard F; Lamy A; Penault-Llorca F; Frébourg T; Michel P; Sabourin JC; Boissière-Michot F
J Clin Oncol; 2009 Mar; 27(7):1122-9. PubMed ID: 19164213
[TBL] [Abstract][Full Text] [Related]
15. RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial.
Sclafani F; Gonzalez D; Cunningham D; Hulkki Wilson S; Peckitt C; Giralt J; Glimelius B; Roselló Keränen S; Wotherspoon A; Brown G; Tait D; Oates J; Chau I
Eur J Cancer; 2014 May; 50(8):1430-6. PubMed ID: 24582914
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713.
Leichman CG; McDonough SL; Smalley SR; Billingsley KG; Lenz HJ; Beldner MA; Hezel AF; Velasco MR; Guthrie KA; Blanke CD; Hochster HS
Clin Colorectal Cancer; 2018 Mar; 17(1):e121-e125. PubMed ID: 29233486
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07.
Helbling D; Bodoky G; Gautschi O; Sun H; Bosman F; Gloor B; Burkhard R; Winterhalder R; Madlung A; Rauch D; Saletti P; Widmer L; Borner M; Baertschi D; Yan P; Benhattar J; Leibundgut EO; Bougel S; Koeberle D
Ann Oncol; 2013 Mar; 24(3):718-25. PubMed ID: 23139259
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapy.
Hsieh YY; Tzeng CH; Chen MH; Chen PM; Wang WS
Cancer Sci; 2012 Apr; 103(4):791-6. PubMed ID: 22321154
[TBL] [Abstract][Full Text] [Related]
19. Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients.
Mekenkamp LJ; Tol J; Dijkstra JR; de Krijger I; Vink-Börger ME; van Vliet S; Teerenstra S; Kamping E; Verwiel E; Koopman M; Meijer GA; van Krieken JH; Kuiper R; Punt CJ; Nagtegaal ID
BMC Cancer; 2012 Jul; 12():292. PubMed ID: 22804917
[TBL] [Abstract][Full Text] [Related]
20. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.
Erben P; Ströbel P; Horisberger K; Popa J; Bohn B; Hanfstein B; Kähler G; Kienle P; Post S; Wenz F; Hochhaus A; Hofheinz RD
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1032-8. PubMed ID: 20947270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]